Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Avapritinib for advanced systemic mastocytosis: analysis of patient-reported outcomes from EXPLORER

Daniel DeAngelo • 2 Dec 2018
ASH 2018
Myeloproliferative Neoplasms Systemic Mastocytosis Avapritinib
EXPLORER

Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, discusses the analysis of the patient-reported outcomes data for avapritinib, a potent inhibitor of KIT D816V for advanced systemic mastocytosis. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Daniel DeAngelo

1:36
IMGN632: a novel CD123-targeted antibody-drug conjugate for R/R BPDCN
Daniel DeAngelo • 3 Dec 2020
1:36
Diagnostic pathology is crucial to guide treatment options
Daniel DeAngelo • 3 Dec 2020
2:29
ASH 2020: Treatment advances in mastocytosis
Daniel DeAngelo • 3 Dec 2020
3:57
Major ALL treatment updates at ASH 2020
Daniel DeAngelo • 3 Dec 2020

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals